Costs of psychotropics for outpatients with bipolar disorder in Japan; the MUSUBI 2016 survey

References

• Bessonova L, Ogden K, Doane MJ, et al. The ecconomic burden of bipolar disorder in the United States: a systematic literature review. Clinicoecon Outcomes Res. 2020;12:1–10. doi: 10.2147/CEOR.S259338.
   PubMed Web of Science ®Google Scholar
• Adachi N, Kubota Y, Goto E, et al. Numbers of patients with mood disorder in JAPC clinics: assumption and interpretation from the collaboration study preliminary survey. J Jpn Assoc Psychiatr Clin. 2016;42:7–9.
   Google Scholar
• Jin H, McCrone P. Cost-of-illness studies for bipolar disorder: systematic review of international studies. Pharmacoeconomics. 2015;33(4):341–353. doi: 10.1007/s40273-014-0250-y.
   PubMed Web of Science ®Google Scholar
• Nishizawa K. Estimated costs of medicine 2001–2017 business years. JRI Rev. 2020;5;77.
   Google Scholar
• Tsuboi T, Suzuki T, Azekawa T, et al. Factors associated with non-remission in bipolar disorder: the multicenter treatment survey for bipolar disorder in psychiatric outpatient clinics (MUSUBI). Neuropsychiatr Dis Treat. 2020;16:883–890.
   Web of Science ®Google Scholar
• Yasui-Furukori N, Adachi N, Kubota Y, et al. Factors associated with doses of mood stabilizers in real-world outpatients with bipolar disorder. Clin Psychopharmacol Neurosci. 2020;18(4):599–606. doi: 10.9758/cpn.2020.18.4.599.
   PubMed Web of Science ®Google Scholar
• Kato M, Adachi N, Kubota Y, et al. Clinical features related to rapid-cycling versus one-year euthymic bipolar disorder patients: the multicenter treatment survey for bipolar disorder in psychiatric clinics (MUSUBI). J Psychiatr Res. 2020;131:228–234. doi: 10.1016/j.jpsychires.2020.09.030.
   PubMed Web of Science ®Google Scholar
• Tokumitsu K, Yasui-Furukori N, Adachi N, et al. Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder. BMC Psychiatry. 2020;20(1):555. doi: 10.1186/s12888-020-02967-5.
   PubMed Web of Science ®Google Scholar
• Adachi N, Azekawa T, Edagawa K, et al. Estimated model of psychotropic polypharmacy for bipolar disorder: analysis using patients’ and practitioners’ parameters in the MUSUBI study. Hum Psychopharmacol. 2021;36(2):e2764. doi: 10.1002/hup.2764.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition text revision, DSM-IV-TR. Arlington: American Psychiatric Association; 2000.
   Google Scholar
• Kubota Y, Adachi N, Goto E, et al. Diagnostic reliability for bipolar disorder of Japanese association of psychiatric clinic (JAPC) members. J Jpn Assoc Psychiatr Clin. 2018;44:717–720.
   Google Scholar
• Ministry of Health, Labor, and Welfare. National health insurance price of medicines. Tokyo: Ministry of Health, Labor, and Welfare; 2016.
   Google Scholar
• Yasui-Furukori N, Shimoda K. Transition of treatment guidelines for bipolar disorder. J Jpn Assoc Psychiatr Clin. 2020;46:351–357.
   Google Scholar
• Simon J, Pari AAA, Wolstenholme J, et al. The costs of bipolar disorder in the United Kingdom. Brain Behav. 2021;11(10):e2351. doi: 10.1002/brb3.2351.
   PubMed Web of Science ®Google Scholar
• Centorrino F, Mark TL, Talamo A, et al. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder. J Clin Psychopharmacol. 2009;29(6):595–600. doi: 10.1097/JCP.0b013e3181bef8a6.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Fu AZ, Liu GG, et al. Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a medicaid programme. Appl Health Econ Health Policy. 2010;​8(3):167–177. doi: 10.2165/11318830-000000000-00000.
   PubMedGoogle Scholar
• Pan YJ, Kuo KH, Yeh L. Healthcre cost, service use, and mortality in major psychiatric disorders in Taiwan. J Affect Disord. 2019;246:112–120. doi: 10.1016/j.jad.​2018.12.046.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mathan K, Sakey S, et al. Cost-of-treatment of clinically stable severe mental illness in India. Indian J Soc Psychiatry. 2017;33(3):262–268. doi: 10.4103/​0971-9962.214600.
   Google Scholar
• Puspitasari IM, Sinuraya RK, Rahayu C, et al. Medication profile and treatment cost estimation among outpatients with schizophrenia, bipolar disorder, depression, and anxiety disorders in Indonesia. Neuropsychiatr Dis Treat. 2020;16:815–828. doi: 10.2147/NDT.S240058.
   PubMed Web of Science ®Google Scholar
• Parker G, McCraw S, Hadzi-Pavlovic D, et al. Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II, and unipolar disorders. J Affect Disord. 2013;149(1–3):46–55. doi: 10.1016/j.jad.2012.10.002.
   PubMed Web of Science ®Google Scholar
• Tafalla M, Salvador-Carulla L, Saiz-Ruiz J, et al. Pattern of healthcare resourse utilization and direct costs associated with manic episodes in Spain. BMC Psychiatry. 2010;10:31. doi: 10.1186/1471-244X-10-31.
   PubMed Web of Science ®Google Scholar
• Esposti LD, Sangiorgi D, Mencacci C, et al. Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study. BMC Psychiatry. 2014;14:282. doi: 10.1186/s12888-014-0282-z.
   PubMed Web of Science ®Google Scholar
• Khan HA, Knusel KD, Calabrese JR, et al. Direct incremental healthcare costs associated with mood disorders in the United States, 2007–2017. J Affect Disord. 2020;273:304–309. doi: 10.1016/j.jad.2020.03.127.
   PubMed Web of Science ®Google Scholar
• Sado M, Yamauchi K, Kawakami N, et al. Cost of depression among adults in Japan in 2005. Psychiatry Clin Neurosci. 2011;65(5):442–450. doi: 10.1111/j.1440-1819.2011.02237.x.
   PubMed Web of Science ®Google Scholar
• Chen P, Dols A, Rej S, et al. Update on the epidemiology, diagnosis, and treatment of mania in old-age bipolar disorder. Curr Psychiatry Rep. 2017;19(8):46. doi: 10.1007/s11920-017-0804-8.
   PubMed Web of Science ®Google Scholar
• Halonen J, Chandola T, Hyde M, et al. Psychotropic medication before and after disability retirement by pre-retirement perceived work-relatedstress. Eur J Public Health. 2020;30:158–163.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Adachi N, Ueda H, et al. A new perspective from the MUSUBI study. J Jpn Assoc Psychiatr Clin. 2021;47:147–152.
   Google Scholar
• Twomey C, Cieza A, Baldwin DS. Utility of functioning in predicting costs of care for patients with mood and anxiety disorders: a prospective cohort study. Int Clin Psychopharmacol. 2017;32(4):205–212. doi: 10.1097/YIC.0000000000000178.
   PubMed Web of Science ®Google Scholar
• Köhler O, Horsdal HT, Baandrup L, et al. Association between global assessment of functioning scores and indicators of functioning, severity, and prognosis in first-time schizophrenia. Clin Epidemiol. 2016;8:323–332. doi: 10.2147/CLEP.S109036.
   PubMed Web of Science ®Google Scholar
• Aedo A, Murru A, Sanchez R, et al. Clinical characterization of rapid cycling bipolar disorder: association with attention deficit hyperactivity disorder. J Affect Disord. 2018;240:187–192. doi: 10.1016/j.jad.2018.07.051.
   PubMed Web of Science ®Google Scholar
• Eid L, Heim K, Doucette S, et al. Bipolar disorder and socioeconomic status: what is the nature of relationship? Int J Bipolar Disord. 2013;1:9.
   PubMedGoogle Scholar